Dr. Lewis Kinter has been a significant force in bringing telemetry to the pharmaceutical industry through his support of telemetry as the gold standard in physiologic monitoring. Among his other contributions to the field, Dr. Kinter helped found the Safety Pharmacology Society and served as its president in 2005. He was also instrumental in bringing together the diverse disciplines of Safety Pharmacology and Toxicology in pharmaceutical research. Dr. Kinter’s studies in these areas led to telemetered blood pressure measurement in animals being recognized as an important part of nonclinical pharmaceutical research and development.
When Dr. Kinter was working on his graduate thesis, it was generally believed that vascular catheterization in conscious rats was not possible, other than in acute situations. However, because Dr. Kinter recognized the cardiovascular response differences in conscious and anesthetized subjects, he made it his mission to use chronic catheterization in conscious rats for more accurate blood sampling and arterial pressure measurements. Dr. Kinter modified his technique over time, first using restraining devices to prevent catheter damage, then moving on to freely-moving rats. Dr. Kinter is also known for his efforts to stave off recurring infections associated with the use of transcutaneous catheters and wires in non-rodent species. Dr. Kinter’s lab pioneered subcutaneous vascular access port technology for blood draws, injections, and infusion, as well as telemetry for blood pressure and electrophysiological monitoring. When these technologies replaced traditional acute monitoring, it resulted in reduced animal use. After the first telemetry implant for measuring blood pressure was brought to market, Dr. Kinter encouraged pharmaceutical R&D organizations to invest in the new scientific tools in order to reduce the number of animals used per study and garner higher quality data. However, a great deal of uncertainty remained as to how the use of telemetry would be treated by various regulatory bodies. As an industry pharmacologist, Dr. Kinter became regarded as a top subject matter expert on telemetry studies and was frequently contacted with questions. He presented and published many papers about Safety Pharmacology, the ICH S7A and S7B guidelines, and the ‘3R’ principles to help answer these questions. Dr. Kinter’s advocacy and support helped telemetry become an accessible tool for industry researchers seeking more accurate data and fewer animals used in their studies.
Dr. Kinter has spent half of his career in discovery pharmacology and the other half in development toxicology, focusing on the efficacy and safety of new drugs, which he views as ‘two sides of the same coin’. Dr. Kinter has a wealth of experience in pharmaceutical research and development and comparative physiology and medicine. His holistic approach to these disciplines has proven to be highly effective in translational research, and in moving considerations of drug safety into drug discovery.
Dr. Kinter recently retired from AstraZeneca and is now the owner and principal scientist of Green Lawn Professional Scientific Consulting, LLC. Dr. Kinter remains active in the scientific community, most recently acting as a Workshop Chairperson and Researcher Sponsor at the 53rd Annual Society of Toxicology Meeting in March of this year. DSI would like to take this opportunity to thank Dr. Kinter for his immense support of telemetry and acknowledge his contributions to the scientific community in support of better data and better science.